Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04316000
Other study ID # QUALI-BANDING-SET
Secondary ID
Status Suspended
Phase
First received
Last updated
Start date November 22, 2019
Est. completion date March 2022

Study information

Verified date September 2021
Source Hospital Universitari de Bellvitge
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To analyze the hypothetical improvement in anxiety degree, quality of life and fear of cancer in patients diagnosed with a small gastrointestinal subeptithelial tumor when opting for the removal of the lesion.


Description:

This "Quality of Life" study is directly related to the "BANDING-SET" study (NCT03247231), whose main aim is to analyze the effectiveness and safety of endoscopic band ligation without resection in the small gastrointestinal subepithelial tumours management. Using three validated tests (Hospital Anxiety and Depression Scale [HADS], Cancer Worry Scale [CWS] and European Five-Dimension Quality of Live test [EuroQol-5D]) patients are evaluated before and after the endoscopic procedure. Three main groups of patients are presented: - GROUP A, in which the subephitelial tumour is successfully removed [hypothesis: anxiety and fear of cancer should decrease]. - GROUP B, in which the subephitelial tumour is not successfully removed due to various reasons (size >15-mm, not technical success,...) [hypothesis: anxiety and fear of cancer shuold be similar before-after]. - GROUP C, in which the subephitelial tumour is not observed or is a benign entity, which does not require further interventions for these patients [hypothesis: anxiety and fear of cancer should decrease].


Recruitment information / eligibility

Status Suspended
Enrollment 150
Est. completion date March 2022
Est. primary completion date March 30, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility INCLUSION CRITERIA: - Age between 18 and 80 years. - Patient able to sign and understand the Informed Consent. - Patient with a previously corroborated diagnosis of a subepithelial tumor (SET) by previous endoscopic ultrasonography (EUS), or possible diagnosis of SET by finding a subepithelial lesion (SEL) in a conventional endoscopy performed that will require a EUS study. - Acceptance by the patient as a candidate of the BANDING-SET study (NCT03247231) of assessment of the effectiveness and safety of band ligation without resection of subepithelial tumors of the digestive tract =15-mm, with the prior signing of the Informed Consent of this study. - Patient that understand the concept of the study and will complete all the time frame until the study end EXCLUSION CRITERIA: - No Informed Consent. - No BANDING-SET study (NCT03247231) Informed Consent. - Patients with functional diversity, unable to understand the nature and possible consequences of the study. - Patients unable to maintain subsequent follow-up (lack of adherence). - Patients with a life expectancy of less than 12 months.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Initial Anxiety and Fear of Cancer Test
Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
Procedure:
Endoscopic band ligation without resection of the subpetihelial tumour.
Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
Other:
1-2 Months Anxiety and Fear of Cancer Test
Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
1 Year Anxiety and Fear of Cancer Test
Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.

Locations

Country Name City State
Spain Hospital Universitari Germans Trias i Pujol (Can Ruti) Badalona Barcelona, Catalonia
Spain Hospital de Sant Pau i de la Santa Creu Barcelona Catalonia
Spain Hospital Universitari de Girona Doctor Josep Trueta Girona Catalonia
Spain Hospital Universitari de Bellvitge L'Hospitalet de Llobregat Barcelona, Catalonia
Spain Hospital Universitari Arnau de Vilanova de Lleida Lleida Catalonia
Spain Hospital Universitari Joan XXIII de Tarragona Tarragona Catalonia
Spain Hospital Universitari Mútua de Terrassa Terrassa Barcelona, Catalonia

Sponsors (1)

Lead Sponsor Collaborator
Francesc Bas-Cutrina

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clin — View Citation

Herdman M, Badia X, Berra S. [EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care]. Aten Primaria. 2001 Oct 15;28(6):425-30. Spanish. — View Citation

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Initial Anxiety degree At 1-2 months, number of patients with a total anxiety score of 8 or more points in the Hospital Anxiety and Depression Scale (HADS), anxiety subescale.
Hospital Anxiety and Depression Scale (HADS), anxiety subescale, legend:
0-7 points: Normal.
8-10 points: Borderline anxiety.
11-21 points: Anxiety disorder.
1-2 months
Primary Initial Fear of Cancer degree At 1-2 months, number of patients with a total fear of cancer score of 11 or more points in the Cancer Worry Scale (CWS).
Cancer Worry Scale (CWS) legend:
6-10 points: Low.
11-15 points: Moderate.
16-20 points: High.
21-24 points: Very high.
1-2 months
Secondary Long-term Anxiety degree At 1 year, number of patients with a total anxiety score of 8 or more points in the Hospital Anxiety and Depression Scale (HADS), anxiety subescale.
Hospital Anxiety and Depression Scale (HADS), anxiety subescale, legend:
0-7 points: Normal.
8-10 points: Borderline anxiety.
11-21 points: Anxiety disorder.
1 year
Secondary Long-term Fear of Cancer degree At 1 year, number of patients with a total fear of cancer score of 11 or more points in the Cancer Worry Scale (CWS).
Cancer Worry Scale (CWS) legend:
6-10 points: Low.
11-15 points: Moderate.
16-20 points: High.
21-24 points: Very high.
1 year
See also
  Status Clinical Trial Phase
Withdrawn NCT02943837 - EUS-guided Fine Needle Aspiration (EUS-FNA) Versus EUS-guided Fine Needle Biopsy (EUS-FNB) for Diagnosis of Subepithelial Tumors N/A
Terminated NCT03247231 - Banding Without Resection in Small Subepithelial Tumours
Completed NCT02666976 - The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Phase 4
Recruiting NCT04695262 - EUS-Elastography and Contrast-Enhanced EUS Diagnostic Accuracy in the Differential Diagnosis of Subepithelial Gastrointestinal Tumors